Therapeutic options here are based on EMA drug approvals with deviating approval details clearly marked. Drugs availability may vary in your country.


AGO – Arbeitsgemeinschaft Gynäkologische Onkologie
AWMF – Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V.
BRCA – Breast Cancer
CNA – Copy Number Alterations
CNV – Copy Number Variation
EMA – European Medicines Agency
FANC – Fanconi Anemia
FFPE – Formalin Fixed Paraffin Embedded tissue
FIGO – Federation Internationale de Gynecology et d´Obstetrique
GI – Genomic Instability
HER-2 – Human Epidermal growth factor Receptor 2
HR – Hormone Receptor
HRD – Homologous Recombination Repair Deficiency
HRR – Homologous Recombination Repair
IARCInternational Agency for Research on Cancer
IHC – Immunohistochemistry
LOH – Loss of Heterozygosity
LST – Large scale State Transition
MLPA – Multiplex Ligation dependent Probe Amplification
MTB – Molecular Tumor Board​​​​​​​
NGS – Next Generation Sequencing
NHEJ – Non Homologous End Joining
OPA – Overall Performance Agreement
PARP – Poly ADP Ribose Polymerase
PARPi – PARP inhibitor
PFS – Progression Free Survival​​​​​​​
QuIPQualitätssicherungs-Initiative Pathologie GmbH
SNP – Single Nucleotide Polymorphism
SOP – Standard Operating Procedure
TAI – Telomeric Allelic Imbalance
TCGA – The Cancer Genome Atlas
TZG – Tumor Cell Content​​​​​​​
VUS –  Variant of Unclear Significance​​​​​​​
WES – Whole Exome​​​​​​​
WGS – Whole Genome